The past few years have been challenging for the biotech.
The company could finally be ready to deliver on years of promise.
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually ...
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
3d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...
A new Crispr-powered optical blood test detects lung cancer biomarkers at sub-attomolar levels, offering earlier molecular detection than conventional PCR or imaging.
Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after ...
A sales partner offered a ray of hope that this company couldn't for itself.
Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results